IL108501A - Antibodies and pharmaceutical compositions containing them - Google Patents

Antibodies and pharmaceutical compositions containing them

Info

Publication number
IL108501A
IL108501A IL10850194A IL10850194A IL108501A IL 108501 A IL108501 A IL 108501A IL 10850194 A IL10850194 A IL 10850194A IL 10850194 A IL10850194 A IL 10850194A IL 108501 A IL108501 A IL 108501A
Authority
IL
Israel
Prior art keywords
antibody
bat
cell line
cells
hybridoma cell
Prior art date
Application number
IL10850194A
Other languages
English (en)
Other versions
IL108501A0 (en
Inventor
Britta Hardy
Abraham Novogrodsky
Original Assignee
Mor Research Applic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Applic Ltd filed Critical Mor Research Applic Ltd
Priority to IL10850194A priority Critical patent/IL108501A/en
Publication of IL108501A0 publication Critical patent/IL108501A0/xx
Priority to CN95192406A priority patent/CN1052733C/zh
Priority to SI9530125T priority patent/SI0742795T1/xx
Priority to EP95910891A priority patent/EP0742795B1/fr
Priority to ES95910891T priority patent/ES2124533T3/es
Priority to RU96116984/13A priority patent/RU2155190C2/ru
Priority to CA002182289A priority patent/CA2182289C/fr
Priority to DE69504955T priority patent/DE69504955T2/de
Priority to US08/380,857 priority patent/US5897862A/en
Priority to AT95910891T priority patent/ATE171461T1/de
Priority to JP52021095A priority patent/JP3478398B2/ja
Priority to DK95910891T priority patent/DK0742795T3/da
Priority to AU18686/95A priority patent/AU693526B2/en
Priority to MD96-0296A priority patent/MD1374G2/ro
Priority to EE9600107A priority patent/EE03285B1/xx
Priority to PCT/US1995/001137 priority patent/WO1995020605A1/fr
Priority to NO19963168A priority patent/NO317020B1/no
Priority to FI963004A priority patent/FI963004A/fi
Priority to MX9603080A priority patent/MX9603080A/es
Priority to LT96-115A priority patent/LT4225B/lt
Priority to LVP-96-317A priority patent/LV11624B/en
Publication of IL108501A publication Critical patent/IL108501A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
IL10850194A 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them IL108501A (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them
PCT/US1995/001137 WO1995020605A1 (fr) 1994-01-31 1995-01-30 Anticorps monoclonaux immunostimulants
JP52021095A JP3478398B2 (ja) 1994-01-31 1995-01-30 免疫刺激性モノクローナル抗体
AU18686/95A AU693526B2 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
EP95910891A EP0742795B1 (fr) 1994-01-31 1995-01-30 Anticorps monoclonaux immunostimulants
ES95910891T ES2124533T3 (es) 1994-01-31 1995-01-30 Anticuerpos monoclonales inmunoestimulantes.
RU96116984/13A RU2155190C2 (ru) 1994-01-31 1995-01-30 Иммуностимуляторные моноклональные антитела
CA002182289A CA2182289C (fr) 1994-01-31 1995-01-30 Anticorps monoclonaux immunostimulants
DE69504955T DE69504955T2 (de) 1994-01-31 1995-01-30 Immunstimulierende monoklonale antikörper
US08/380,857 US5897862A (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
AT95910891T ATE171461T1 (de) 1994-01-31 1995-01-30 Immunstimulierende monoklonale antikörper
CN95192406A CN1052733C (zh) 1994-01-31 1995-01-30 免疫刺激单克隆抗体
DK95910891T DK0742795T3 (da) 1994-01-31 1995-01-30 Immunstimulerende monoklonale antistoffer
SI9530125T SI0742795T1 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies
MD96-0296A MD1374G2 (ro) 1994-01-31 1995-01-30 Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică
EE9600107A EE03285B1 (et) 1994-01-31 1995-01-30 Immuunsust stimuleerivad monoklonaalsed antikehad
MX9603080A MX9603080A (es) 1994-01-31 1996-07-29 Anticuerpos monoclonales inmuno-estimulantes.
NO19963168A NO317020B1 (no) 1994-01-31 1996-07-29 Immunstimulatoriske monoklonale antistoffer
FI963004A FI963004A (fi) 1994-01-31 1996-07-29 Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
LT96-115A LT4225B (en) 1994-01-31 1996-07-30 Immuno-stimulatory monoclonal antibodies
LVP-96-317A LV11624B (en) 1994-01-31 1996-09-06 Immuno-stimulatory monoclonal antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
IL108501A0 IL108501A0 (en) 1994-05-30
IL108501A true IL108501A (en) 1998-10-30

Family

ID=11065761

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them

Country Status (20)

Country Link
US (1) US5897862A (fr)
EP (1) EP0742795B1 (fr)
JP (1) JP3478398B2 (fr)
CN (1) CN1052733C (fr)
AT (1) ATE171461T1 (fr)
AU (1) AU693526B2 (fr)
CA (1) CA2182289C (fr)
DE (1) DE69504955T2 (fr)
DK (1) DK0742795T3 (fr)
EE (1) EE03285B1 (fr)
ES (1) ES2124533T3 (fr)
FI (1) FI963004A (fr)
IL (1) IL108501A (fr)
LT (1) LT4225B (fr)
LV (1) LV11624B (fr)
MD (1) MD1374G2 (fr)
MX (1) MX9603080A (fr)
NO (1) NO317020B1 (fr)
RU (1) RU2155190C2 (fr)
WO (1) WO1995020605A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
DE10161767T1 (de) 2002-07-03 2018-06-07 Honjo Tasuku Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
WO2006021955A2 (fr) * 2004-08-23 2006-03-02 Mor Research Applications Ltd. Utilisation d'anticorps monoclonaux bat pour l'immunotherapie
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
EP2170959B1 (fr) * 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Anticorps dirigés contre le récepteur humain de mort programmée pd-1
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
MD3972C2 (ro) * 2009-03-11 2010-07-31 Ион МЕРЕУЦЭ Remediu şi metodă de tratament al stărilor precanceroase
CA2840018C (fr) 2011-07-24 2019-07-16 Curetech Ltd. Variants d'anticorps monoclonaux immunomodulateurs humanises
EP3757130A1 (fr) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Méthodes de traitement de cancers hématologiques
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JP6681905B2 (ja) 2014-09-13 2020-04-15 ノバルティス アーゲー Ａｌｋ阻害剤の併用療法
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
PL3328419T3 (pl) 2015-07-30 2021-12-27 Macrogenics, Inc. Cząsteczki wiążące pd-1 i sposoby ich zastosowania
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
KR20180054824A (ko) 2015-09-29 2018-05-24 셀진 코포레이션 Pd-1 결합 단백질 및 이의 사용 방법
SG11201803520PA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
KR102424513B1 (ko) 2015-12-14 2022-07-25 마크로제닉스, 인크. Pd-1 및 ctla-4과의 면역반응성을 가진 이중특이적 분자, 및 이것의 사용 방법
EP3471753A1 (fr) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 et cytokines il-2
BR112019004733A2 (pt) 2016-09-19 2019-05-28 Celgene Corp métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
MA50948A (fr) 2016-12-07 2020-10-14 Agenus Inc Anticorps et procédés d'utilisation de ceux-ci
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation

Also Published As

Publication number Publication date
DK0742795T3 (da) 1999-06-14
MD1374G2 (ro) 2000-09-30
DE69504955T2 (de) 1999-05-27
DE69504955D1 (de) 1998-10-29
EP0742795B1 (fr) 1998-09-23
JP3478398B2 (ja) 2003-12-15
JPH09508390A (ja) 1997-08-26
ES2124533T3 (es) 1999-02-01
NO963168L (no) 1996-09-27
NO317020B1 (no) 2004-07-26
LT4225B (en) 1997-10-27
RU2155190C2 (ru) 2000-08-27
ATE171461T1 (de) 1998-10-15
IL108501A0 (en) 1994-05-30
FI963004A0 (fi) 1996-07-29
NO963168D0 (no) 1996-07-29
FI963004A (fi) 1996-09-27
LT96115A (en) 1997-05-26
CA2182289A1 (fr) 1995-08-03
AU1868695A (en) 1995-08-15
CN1145077A (zh) 1997-03-12
AU693526B2 (en) 1998-07-02
LV11624B (en) 1997-06-20
CN1052733C (zh) 2000-05-24
WO1995020605A1 (fr) 1995-08-03
MD1374F2 (en) 1999-12-31
CA2182289C (fr) 2003-10-21
EE03285B1 (et) 2000-08-15
LV11624A (en) 1996-12-20
EP0742795A1 (fr) 1996-11-20
MX9603080A (es) 1998-01-31
US5897862A (en) 1999-04-27

Similar Documents

Publication Publication Date Title
US5897862A (en) Immuno-stimulatory monoclonal antibodies
WO1995020605A9 (fr) Anticorps monoclonaux immunostimulants
MXPA96003080A (en) Monoclonal antibodies immuno-estimulan
US7794710B2 (en) Methods of enhancing T cell responsiveness
ES2579277T3 (es) Utilización combinada de un agente de bloqueo CTLA-4 y una terapia linfotóxica en el tratamiento de tumores
Seon et al. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
US6852320B2 (en) T cell inhibitory receptor compositions and uses thereof
US20210214436A1 (en) Multi-specific binding proteins and improvements thereon
US6197298B1 (en) Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
AU2002219229B9 (en) Means for the diagnosis and therapy of CTCL
CA2179196A1 (fr) Procede de prevention ou de traitement de maladies caracterisees par des cellules neoplasiques exprimant le cd40
KR19990022650A (ko) 사람 ｂ7.1 및/또는 ｂ7.2 영장류화된 형태에 특이적인 원숭이 단일클론성 항체 및 이의 약제학적 조성물
JP6682438B2 (ja) 癌治療のための改善された細胞組成物および方法
CN109195988A (zh) 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
CN106414500A (zh) 抗-wt1/hla双特异性抗体
AU2015300006B2 (en) Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
KR20110085038A (ko) 항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
Hardy et al. A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice
Saha et al. CTLA4 (CD152) modulates the Th subset response and alters the course of experimental Leishmania major infection
Zalman et al. The cytolytic protein of human lymphocytes related to the ninth component (C9) of human complement: isolation from anti-CD3-activated peripheral blood mononuclear cells.
Hu Overcome the impairment of NK cells for icon and antibody immunotherapy of cancer
Wang et al. Targeting solid tumors via T cell receptor complementarity-determining region 3δ in an engineered antibody
JPH01126558A (ja) 抗体依存性細胞性細胞毒性の測定方法
Kudo et al. Specific targeting immunotherapy of cancer with bispecific antibodies
US20240293546A1 (en) D2c7 egfr and egfr viii bi-specific chimeric antigen receptor constructs and methods of making and using same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
NP Permission for amending the patent specification granted (section 66, patents law 1967)
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired